Audit: QRS - Foam Rolling for Health & Longevity
Audit conducted on 14/09/2026 08:11 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 93 |
| Passed | 84 |
| Failed | 0 |
| N/A | 9 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Spot-checked every populated span against the ER: protocol cells vs ER lines 353/355/361, time cells vs 405/158/170, benefit and risk tiers vs the ER H4 headings, all 11 monitoring rows vs the ER table (lines 437-447), cadence vs line 433, gates vs lines 308-331. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | Hedges carried across: “lasting adaptation not tested” (ER 170), “perturbed in a still-contested direction” (ER 442), “not improved by rolling” (ER 439), “No established target; change from personal baseline” (ER 443). |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | No strengthening or softening found; the 30-minute bound on the vascular effect is kept explicit in the Time to effect cell, and the contraindication thresholds (90 days, T-score -2.5, platelets 50,000/uL, INR 3.5) match ER lines 324-331 exactly. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come only from the ER “Populations who should avoid Foam Rolling” list; Key Interactions only from the ER caution bullets; no Benefit- or Risk-Modifying Factor is surfaced as a gate or side effect. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | No PMIDs, study names, author names, NCT identifiers or brand names appear anywhere in the QRS. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind are introduced. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER register: measured, non-promotional, explicit about what is unresolved. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Expert and data-driven (thresholds, durations, percentages) while remaining readable; the flat statement of what rolling does and does not do is empowering rather than hedged. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Presents evidence and ranges; no directives addressed at a patient. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Gates and monitoring rows state facts and thresholds; the template disclaimer is intact at lines 756-761. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommended”, “advised”, “you should” or comparable construction anywhere in the file. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person address; verified by scan for “you”/”your”. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain wording throughout; the clinical terms retained (osteomyelitis, myositis ossificans, haematoma) are the ER’s own and are load-bearing in decision gates, where 8.4 forbids adding glosses. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every field is a short phrase; semicolon-joined tier lists and terse table cells throughout. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed - no direct address. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Content selection (dosing, programme duration, arterial stiffness, PWV, HRV, skeletal muscle index, bone density) targets a proactive, risk-aware audience. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Presents a 3-5 session weekly, >4-week programme and an 11-marker monitoring panel without softening the effort involved. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | No general-population simplification; retains PWV, RMSSD, skeletal muscle index and T-score reasoning. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | At-a-glance states “No strength or power gain; harms are minor”, and risks_low retains “no performance gain and displaced warm-up time” - the opportunity-cost framing that matters to this audience specifically. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | No occurrence of “anti-aging”; the page title uses “Longevity” per the ER canonical_topic. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | Formal register maintained; at-a-glance uses “self-applied pressure technique”, “arterial stiffness” and “harms” (the ER Conclusion’s own term, line 482), with no consumer-grade route or product phrasing. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fixed strings verified byte-identical to the template: “Protocol” (line 440), “Time to effect” (477), “Benefits” (519), “Risk & Side Effects” (573), “Monitoring” (590), “Qualitative Assessment” (731), “Contraindications” (539), “Key Interactions” (554), the four tier labels, and “Marker”/”Target”/”Why” (594-596). |
| 3.2 | All “…” from the [qrs_template] are present in the the QRS. | 🟢 | A normalised structural diff against QRS.html shows every template span present; marker_#* is expanded to marker_1..11 and qualitative_item# to qualitative_item_1..6, with no span added or dropped. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The same diff shows zero changes outside the frontmatter values and the checklist-governed spans - CSS, comments, header scaffolding and footer are untouched. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No ER section that maps to a QRS variable is empty; the ER High-risk tier carries explanatory prose (line 242), not an empty-state phrase, and is handled under 13.5. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels are the ER bold labels verbatim: “Standard session structure” (ER 353), “Dose per region” (ER 355), “Programme duration” (ER 361). |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No label paraphrased or invented; monitoring marker names reproduce the ER table’s Biomarker column. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Scan confirms no emoji characters in the file; tiers are conveyed by bold labels and CSS only. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Content is condensed rather than extended: each tier is a single semicolon-joined line, gate items are stripped of all mechanism and mitigation text, and monitoring “Why” cells are cut to one clause - the 11 markers and 6 qualitative items are mandated in full by 14.2 and 15.2. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | The metadata comment opens at line 2, immediately after “<!doctype html>” on line 1, before any other comment or head content. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | YAML opens with “—” at line 3 and closes with “—” at line 13, inside the single comment that ends at line 14. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed in an HTML comment; no value is duplicated into any rendered element. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | All values trimmed; only duration is quoted, correctly, because “00:03” contains a colon. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | Line 4: er_filename: foam_rolling_2026-0914-0620_Opus_ER.md - matches the ER on disk. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | Line 5: qrs_prompt_version: 26.9.11 - matches the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | Line 6: qrs_creation_date: 2026-0914-0746 - correct YYYY-MMDD-HHMM form. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | Line 7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” is a single word with no version or qualifier. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | Line 8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” is nickname plus version number with no additional qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | Line 9: qrs_filename: foam_rolling_2026-0914-0620_Opus_QRS.html - matches the actual filename. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys: no stray whitespace and no unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | Line 22: “Foam Rolling for Health & Longevity - Quick Reference Sheet” - canonical_topic plus the required suffix, with & entity-encoded. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | Line 417: “Foam Rolling for Health & Longevity” - canonical_topic, entity-encoded. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | Line 421: 09/14/2026, the MM/DD/YYYY form of qrs_creation_date 2026-0914. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | Line 425: “Opus 5”, matching qrs_creator_ai_fullname. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header (lines 415-428) is identical to the template - no badge, AKA line, version stamp, audit date or variant marker. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Line 433 condenses the ER Conclusion (lines 478-482): what it is, the two best-supported effects, the vascular effect, and the two limits. |
| 7.2 | [at_a_glance] is no longer than 60 words | 🟢 | 56 words, within the 60-word cap. |
| 7.3 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Each clause traces to the Conclusion: “single inexpensive object and about ten minutes” (478), “joints move further after rolling” (478), “muscle soreness … reported as less severe” (478), “blood pressure falling for about half an hour” (478), “does not make anyone stronger or more powerful” (480), “Harms are minor” (482). |
| 7.4 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms or specialist classifications; “large arteries”, “less stiff” and “harms” are non-specialist wording. |
| 7.5 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year, sample size or p-value. |
| 7.6 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No effect size, confidence interval, hazard ratio or percentage; the ER’s 11% PWV figure and the pooled SMDs are all excluded. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All eight items trace to the ER “Key Interactions & Contraindications” section, lines 322-331. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | All eight ER “Populations who should avoid Foam Rolling” entries are present in [stop_items], lines 542-549, none added. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | Each of the eight is a separate <li> element inside the [stop_items] span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Mechanism, examples and rationale stripped (e.g. ER’s “as in long-standing diabetes with an absent 10 g monofilament response” reduced to “with sensory loss”); no dash-trailing clause remains in any item. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | Thresholds and windows all preserved: “(within 90 days, or anticoagulation not yet therapeutic)”, “under 6 weeks old”, “(spine or hip T-score -2.5 or below)”, “for thoracolumbar rolling”, “Platelets below 50,000/uL, or international normalised ratio above 3.5”. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its contraindication list (lines 324-331). |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | Section is populated, and the ER does identify populations that should avoid the intervention, so the empty-only condition is respected. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty, so no absence comment is required. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All seven items trace to the ER “Key Interactions & Contraindications” caution bullets, lines 308-320. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | All seven ER caution bullets are present, lines 557-563, and none duplicates a Contraindication entry. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | Each of the seven is a separate <li> element inside the [caution_items] span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every “Caution. …” rationale and “Mitigation: …” clause from ER lines 308-320 is stripped; no dash-trailing clause remains. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All six example-drug and example-modality lists preserved in parentheses; only the ER’s inline glosses (“blood-pressure-lowering drugs:”, “painkillers:”, “creams producing a warming or cooling sensation:”) are dropped, with the drug names intact. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | N/A | The ER uses no ranking notation inside parentheses in its caution bullets (lines 308-320). |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | Section is populated, and the ER does identify interactions, so the empty-only condition is respected. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. | N/A | The section is not empty, so no absence comment is required. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three sets derive from the ER “Therapeutic Protocol” section, lines 351-375. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Session structure (ER 353), per-region dose (ER 355) and programme duration (ER 361) are the three dosing decisions the ER quantifies; the remaining bullets are technique variants and subgroup adjustments. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER Protocol section supplies twelve actionable aspects, so no set is unused. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | All nine action fields are populated with ER-derived content and no placeholder text remains. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Range of motion, muscle soreness and arterial stiffness/blood pressure are the only outcomes for which the ER states a time course (lines 405, 158, 170). |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | All three sit in the ER High tier and appear in the ER’s own High-tier order: joint range of motion (150), delayed-onset muscle soreness (156), arterial stiffness and blood pressure (168). |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER supplies three distinct time-to-effect aspects, so no set is unused. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | All nine time fields are populated with ER-derived content: “Single session”/”Decays in ~10 min … >4 weeks” (ER 405), “24 to 72 hours”/”grows over the first two days” (ER 405, 158), “About 30 minutes”/”lasting adaptation not tested” (ER 170). |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information, so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All four tiers derive from the ER “Expected Benefits” section, lines 144-220. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at lines 521, 524, 527, 530. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-joined list of bare benefit names; all magnitudes, confidence intervals, trial counts, mechanisms and the ER’s “Conflicted” flags are dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives anywhere in the four benefit spans. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | N/A | All four ER benefit tiers contain items, so no span needs hiding. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All tiers derive from the ER “Potential Risks & Side Effects” section, lines 236-290. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at lines 575, 576, 579, 582. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each tier is a semicolon-joined list of bare risk names; the ER’s Magnitude paragraphs, survey percentages, pooled effect sizes and consensus figures are all dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | No parenthetical content survives anywhere in the four risk spans. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | The ER states “No risk reaches High” (line 242), and [risks_high] at line 575 is correctly emptied with style=”display: none” rather than carrying empty-state text. |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | All eleven rows derive from the ER “Monitoring Protocol & Defining Success” biomarker table, lines 435-447. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All eleven ER biomarkers are present in order: sit-and-reach, passive straight-leg raise, ankle dorsiflexion, resting blood pressure, pulse wave velocity, RMSSD, pressure pain threshold, hs-CRP, skeletal muscle index, platelets/INR, bone mineral density T-score. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | Line 725 carries the ER cadence from line 433: range of motion at 4 and 8 weeks, blood pressure monthly, arterial stiffness, heart rate variability and bone density every 6-12 months. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | All six items derive from the ER qualitative-marker list, lines 449-456. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers are present at lines 734-749: morning stiffness, peak soreness, discomfort at fixed pressure, ease of end range, sleep quality, and bruising/numbness/tingling/headache. |
Issues 14/09/2026 08:11
Pass rate 100.00%. No issues found.
Issues 14/09/2026 08:03
- 1.2 — Hedge dropped from qualitative marker: [qualitative_item_3] at line 740 reads “which falls as tissue sensitivity adapts”, dropping the ER’s hedge at line 453 (“which typically falls as tissue sensitivity adapts”) and presenting a typical tendency as an unqualified one.
Fixes 14/09/2026 08:03
- 1.2 — Hedge restored in qualitative marker: Restored the ER’s hedge in [qualitative_item_3], changing “which falls as tissue sensitivity adapts” to “which typically falls as tissue sensitivity adapts” to match ER line 453.
Issues 14/09/2026 07:51
- 4.5 — Sheet overflows one A4 page: At the template’s own print metrics the populated content runs roughly two A4 pages, driven by the un-condensed Contraindications gate (QRS 542-549, ~19 wrapped lines), the Monitoring table (QRS 600-720, ~25 lines) and long Protocol sub-lines and At-A-Glance text carried over at near-ER length.
Fixes 14/09/2026 07:51
- 4.5 — Contraindications gate condensed: Trimmed all eight [stop_items] to their key facts while keeping every threshold and time window (e.g. “Established osteoporosis with a spine or hip T-score of −2.5 or below, for direct thoracolumbar rolling” → “Osteoporosis (spine or hip T-score −2.5 or below), for thoracolumbar rolling”), cutting the gate from ~19 to ~13 wrapped lines.
- 4.5 — Key Interactions gate condensed: Shortened the two longest [caution_items] without dropping any example drug or agent (“beetroot or dietary nitrate” → “nitrate”; “sauna and hot baths, percussive massage devices, blood-flow-restriction training” → “sauna, percussive devices, blood-flow restriction”).
- 4.5 — Monitoring table cells condensed: Reduced fourteen over-long Target and Why cells to single-line length while preserving every value and reason (e.g. “Muscle mass divided by height squared, which predicts the size of the vascular response” → “Muscle mass / height²; predicts the vascular response size”), and tightened [monitoring_cadence].
- 4.5 — Protocol and Time-to-Effect sub-lines shortened: All six
subspans cut from two to three wrapped lines down to one to two (e.g. “30 to 120 seconds each, one to two sets, roughly one slow pass every two seconds” → “30–120 s each, 1–2 sets, one slow pass per 2 s”). - 4.5 — At-A-Glance, Benefits and Risks tightened: Removed redundant words from [at_a_glance] (58 → 56 words) and from the Benefits/Risks tier lists (e.g. “accelerated recovery of sprint and strength performance” → “faster sprint and strength recovery”), with no fact, direction or hedge dropped.
- 4.5 — Qualitative Assessment items tightened: Trimmed four of the six items to their measurable core (e.g. “Sleep quality and time to fall asleep on evenings following a whole-body session” → “Sleep quality and time to fall asleep after a whole-body session”), all six ER markers retained.
Total visible sheet text reduced from ~6,000 to ~5,100 characters. The eight Contraindications, seven Key Interactions, eleven monitoring biomarkers and six qualitative markers are all retained, as items 8.2, 9.2, 14.2 and 15.2 require.